TR201910744T4 - Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar. - Google Patents

Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar. Download PDF

Info

Publication number
TR201910744T4
TR201910744T4 TR2019/10744T TR201910744T TR201910744T4 TR 201910744 T4 TR201910744 T4 TR 201910744T4 TR 2019/10744 T TR2019/10744 T TR 2019/10744T TR 201910744 T TR201910744 T TR 201910744T TR 201910744 T4 TR201910744 T4 TR 201910744T4
Authority
TR
Turkey
Prior art keywords
gdf
monoclonal antibodies
directed against
antibodies directed
differentiation factor
Prior art date
Application number
TR2019/10744T
Other languages
English (en)
Inventor
Wischhusen Jörg
junker Markus
Müller Thomas
Saremba Stefan
Original Assignee
Univ Wuerzburg J Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wuerzburg J Maximilians filed Critical Univ Wuerzburg J Maximilians
Publication of TR201910744T4 publication Critical patent/TR201910744T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Mevcut buluş, burada açıklanan monoklonal antikorları üretebilen monoklonal anti-insan-GDF-15 antikorları, farmasötik bileşimler, kitler, yöntemler ve kullanımlar ve hücre dizileri ile ilgilidir. Mevcut buluş ayrıca kanser büyümesini inhibe edebilen insan GDF-15'ine yönelik yeni antikorlar ile ilgilidir.
TR2019/10744T 2012-09-26 2013-09-26 Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar. TR201910744T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12186185 2012-09-26

Publications (1)

Publication Number Publication Date
TR201910744T4 true TR201910744T4 (tr) 2019-08-21

Family

ID=46888333

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10744T TR201910744T4 (tr) 2012-09-26 2013-09-26 Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar.

Country Status (23)

Country Link
US (3) US20150239968A1 (tr)
EP (2) EP2900263B1 (tr)
JP (4) JP2015532271A (tr)
KR (1) KR101838786B1 (tr)
CN (1) CN104853775B (tr)
AU (2) AU2013322628B2 (tr)
CA (1) CA2886207C (tr)
CY (1) CY1121832T1 (tr)
DK (1) DK2900263T3 (tr)
ES (1) ES2742287T3 (tr)
HK (1) HK1210950A1 (tr)
HR (1) HRP20191326T1 (tr)
HU (1) HUE044363T2 (tr)
IL (2) IL237828B (tr)
LT (1) LT2900263T (tr)
NZ (1) NZ706189A (tr)
PL (1) PL2900263T3 (tr)
PT (1) PT2900263T (tr)
RS (1) RS59045B1 (tr)
SG (1) SG11201502279YA (tr)
SI (1) SI2900263T1 (tr)
TR (1) TR201910744T4 (tr)
WO (1) WO2014049087A1 (tr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150239968A1 (en) 2012-09-26 2015-08-27 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
AU2014352843B2 (en) 2013-11-21 2020-03-05 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
GB2524553C (en) * 2014-03-26 2017-07-19 Julius-Maximilians-Universitãt Würzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
BR122023027559A2 (pt) 2014-03-26 2024-01-30 Julius-Maximilians-Universität Würzburg Anticorpos monoclonais para fator de crescimento e diferenciação 15 (gdf-15), estojo compreendendo os mesmos, vetor de expressão que codifica os mesmos e linhagem de célula capaz de produzir os mesmos
GB2524552B (en) * 2014-03-26 2017-07-12 Julius-Maximilians-Universitãt Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
EP3157953B1 (en) 2014-06-20 2021-12-22 Aveo Pharmaceuticals, Inc. Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
WO2016019368A1 (en) * 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
EP4218809A3 (en) 2015-10-02 2023-08-09 Julius-Maximilians-Universität Würzburg Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
CA3000290C (en) 2015-10-02 2023-02-21 Julius-Maximilians-Universitat Wurzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
ITUB20154769A1 (it) * 2015-11-04 2017-05-04 Centro Di Riferimento Oncologico Cro Irccs Aviano Anticorpo monoclonale anti-BARF1
EP3425392A4 (en) * 2016-02-29 2020-02-05 Public University Corporation Yokohama City University METHOD FOR DETECTING CASTRATION-RESISTANT PROSTATE CANCER AND REAGENT REAGENT
AU2017228489A1 (en) * 2016-03-04 2018-09-06 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
TWI815793B (zh) 2016-03-31 2023-09-21 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
CN109071647B (zh) * 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途
CN107782900A (zh) * 2016-08-31 2018-03-09 朱海燕 人生长分化因子‑15的检测试纸组件
KR102010652B1 (ko) * 2017-08-21 2019-08-13 서울대학교병원 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법
WO2021111636A1 (ja) * 2019-12-06 2021-06-10 大塚製薬株式会社 抗ｇｄｆ１５抗体
CN112698042A (zh) * 2020-12-17 2021-04-23 北京赛诺浦生物技术有限公司 检测人生长分化因子-15的荧光免疫层析试纸条及其制备方法和应用
CA3215737A1 (en) 2021-03-31 2022-10-06 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
CN113252905A (zh) * 2021-05-12 2021-08-13 北京赛诺浦生物技术有限公司 人生长分化因子-15磁微粒化学发光检测试剂盒及其应用
AU2022328390A1 (en) 2021-08-10 2024-03-21 Adimab, Llc Anti-gdf15 antibodies, compositions and uses thereof
CN113702647B (zh) * 2021-08-31 2024-03-15 普十生物科技(北京)有限公司 人生长分化因子15即时检测试剂盒、其制备方法及其应用
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023217068A1 (zh) * 2022-05-09 2023-11-16 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
CA2372119A1 (en) 1999-05-17 2000-11-23 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrie B Von Pharmaka Mbh Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
WO2002020759A2 (en) * 2000-09-08 2002-03-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
EP3476861A1 (en) 2004-01-07 2019-05-01 Novartis Vaccines and Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
EP2774620A1 (en) 2004-04-13 2014-09-10 St Vincent's Hospital Sydney Limited Method for modulating weight loss
US20100278843A1 (en) 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
JP2011502106A (ja) 2007-10-09 2011-01-20 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン−１を除去又は不活性化して悪液質を治療する方法
EP2331575B1 (en) 2008-09-29 2014-05-28 Roche Glycart AG Antibodies against human il 17 and uses thereof
US20120309697A1 (en) * 2009-10-28 2012-12-06 Samuel Norbert Breit Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
CN101852804B (zh) * 2010-03-29 2013-06-12 中国医学科学院病原生物学研究所 Gdf15蛋白的抗体的新用途
MX355060B (es) * 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) * 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
JP2015506373A (ja) 2012-01-26 2015-03-02 アムジエン・インコーポレーテツド 成長分化因子１５（ｇｄｆ−１５）ポリペプチド
US20150239968A1 (en) 2012-09-26 2015-08-27 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
AR094271A1 (es) 2012-12-21 2015-07-22 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15
CA3000290C (en) * 2015-10-02 2023-02-21 Julius-Maximilians-Universitat Wurzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
EP4218809A3 (en) * 2015-10-02 2023-08-09 Julius-Maximilians-Universität Würzburg Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
EP3841121A2 (en) 2018-08-20 2021-06-30 Pfizer Inc. Anti-gdf15 antibodies, compositions and methods of use

Also Published As

Publication number Publication date
US20150239968A1 (en) 2015-08-27
CA2886207C (en) 2021-01-05
LT2900263T (lt) 2019-10-10
PL2900263T3 (pl) 2019-10-31
HUE044363T2 (hu) 2019-10-28
WO2014049087A1 (en) 2014-04-03
HK1210950A1 (en) 2016-05-13
KR101838786B1 (ko) 2018-03-15
PT2900263T (pt) 2019-07-29
SI2900263T1 (sl) 2019-09-30
IL237828A0 (en) 2015-05-31
SG11201502279YA (en) 2015-04-29
ES2742287T3 (es) 2020-02-13
IL277392A (en) 2020-11-30
IL237828B (en) 2020-10-29
CY1121832T1 (el) 2020-07-31
HRP20191326T1 (hr) 2019-11-01
EP2900263B1 (en) 2019-06-05
JP2015532271A (ja) 2015-11-09
AU2013322628A1 (en) 2015-04-09
DK2900263T3 (da) 2019-07-29
JP2018019690A (ja) 2018-02-08
NZ706189A (en) 2016-09-30
US11891436B2 (en) 2024-02-06
EP3590537A1 (en) 2020-01-08
US20180305447A1 (en) 2018-10-25
US10781251B2 (en) 2020-09-22
CN104853775B (zh) 2023-10-20
BR112015006829A2 (pt) 2017-11-21
JP7270522B2 (ja) 2023-05-10
EP2900263A1 (en) 2015-08-05
JP2022017219A (ja) 2022-01-25
JP2020043855A (ja) 2020-03-26
JP6670275B2 (ja) 2020-03-18
AU2017203523A1 (en) 2017-06-15
CN104853775A (zh) 2015-08-19
US20210054060A1 (en) 2021-02-25
AU2013322628B2 (en) 2017-03-02
RS59045B1 (sr) 2019-08-30
CA2886207A1 (en) 2014-04-03
AU2017203523B2 (en) 2019-02-07
KR20150082229A (ko) 2015-07-15

Similar Documents

Publication Publication Date Title
TR201910744T4 (tr) Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar.
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
EA201791393A2 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
EA201691266A1 (ru) Анти-cd3 антитела и способы применения
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
AU2014247175A8 (en) Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201400875A1 (ru) Антитела к cd47 и способы их применения
IN2014MN01879A (tr)
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
NZ604003A (en) Monoclonal antibodies against her2
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
MX2019009654A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
MX2013004897A (es) Anticuerpos y composiciones anti-her3.
EA201201357A1 (ru) Антитела к cd40
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
EA201491107A1 (ru) Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
BR112014000181A2 (pt) bloqueamento de anticorpo agr2 e uso dos mesmos
EA201390467A1 (ru) Композиции антител и способы применения
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.